BMN 255
255-102
Phase 1 small_molecule terminated
Quick answer
BMN 255 for Hyperoxaluria is a Phase 1 program (small_molecule) at BIOMARIN PHARMACEUTICAL INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BIOMARIN PHARMACEUTICAL INC
- Indication
- Hyperoxaluria
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated